, Volume 30, Issue 4, pp 283–291

High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults

  • Tinna Traustadóttir
  • Anthoney A. Stock
  • S. Mitchell Harman


3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are lipid-lowering agents widely employed for atherosclerosis prevention. HMG-CoA reductase blockade reduces skeletal muscle coenzyme Q10 (CoQ10) levels and mitochondrial respiratory chain activities and may produce mild to severe skeletal muscle myopathy. This study investigated whether high-dose statin treatment would result in measurably decreased exercise capacity in older men and women. Maximal oxygen consumption, aerobic endurance, oxygen uptake kinetics, maximal strength, muscular power, and muscular endurance were measured before and after 12 weeks of statin treatment (simvastatin, 80 mg/day) in nine men and one woman, ages 55–76 years, with LDL-cholesterol levels >3.3 mmol/l (mean = 4.2 ± 0.2 mmol/l). Myalgia symptoms were assessed every 4 weeks. As expected, statin treatment resulted in significant decreases in LDL- and total-cholesterol levels (P < 0.01) with no significant changes in HDL-cholesterol or triglyceride levels. No significant changes were observed in aerobic capacity, endurance, oxygen kinetics or any measures of muscle function. No subject reported symptoms of myalgia, cramps, or weakness during the study. In the absence of myalgia or myopathic symptoms, high-dose simvastatin treatment did not impair exercise capacity in hyperlipidemic older individuals. We conclude that decreases in intramuscular CoQ10, in most patients on high dose statin treatment may not be clinically relevant, due to inter-individual variability in the degree of CoQ10 depletion, sensitivity of muscle to decreases in CoQ10, or both.


Aging Simvastatin Vo2max Strength O2 uptake kinetics Myalgia 


  1. American College of Sports Medicine (1991) Guidelines for exercise testing and prescription, 4th edn. Lea & Febiger, PhiladelphiaGoogle Scholar
  2. Baechle TR, Earle RW, Wathen D (2000) Resistance training. In: Baechle TR, Earle RW (eds) Essentials of strength training and conditioning. 2nd edn. Human Kinetics, Champaign, pp 406–409Google Scholar
  3. Bruckert E, Hayem G, DeJager S, Yau C, Begaud B (2006) Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—The PRIMO Study. Cardiovasc Drugs Ther 19:403–414CrossRefGoogle Scholar
  4. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al (2004) Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504Google Scholar
  5. Caso G, Kelly P, McNurian MA, Lawson WE (2007) Effect of Coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 99:1409–1412PubMedCrossRefGoogle Scholar
  6. Conley K, Jubrias S, Amara CE, Marcinek DJ (2007) Mitochondrial dysfunction: Impact on exercise performance and cellular aging. Exerc Sport Sci Rev 35:43–49PubMedCrossRefGoogle Scholar
  7. Davidson MH, Robinson JG (2007) Safety of aggressive lipid management. J Am Coll Cardiol 49:1753–1762PubMedCrossRefGoogle Scholar
  8. England J, Walsh J, Stewart P, Boyd I, Rohan A, Halmagyi G (1995) Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors—simvastatin and pravastatin. Aust N Z J Med 25:374–375PubMedGoogle Scholar
  9. Franc S, DeJager S, Bruckert E, Chauvenet M, Giral P, Turpin G (2003) A comprehensive description of muscle symptoms associated with lipid lowering drugs. Cardiovasc Drugs Ther 17:459–465PubMedCrossRefGoogle Scholar
  10. Gaist D, Rodriguez L, Huerta C, Hallas J, Sindrup S (2001) Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidmiology 12:565–569CrossRefGoogle Scholar
  11. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H (1997) Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 336:332–336PubMedCrossRefGoogle Scholar
  12. Kaikkonen J, Nyyssönen K, Tuomainen T-P, Ristonmaa U, Salonen JT (1999) Determinants of plasma coenzyme Q10 in humans. FEBS Lett 443:163–166PubMedCrossRefGoogle Scholar
  13. Kohrt W, Malley M, Coggan A, Spina R, Ogawa T, Ehsani A et al (1991) Effects of gender, age, and fitness level on response of VO2 max to training in 60–71 yr olds. J Appl Physiol 71:2004–2011PubMedGoogle Scholar
  14. Lass A, Kwong LK, Sohal RS (1999) Mitochondrial coenzyme Q content and aging. Biofactors 9:199–205PubMedGoogle Scholar
  15. Nawarskas JJ (2005) HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev 13:76–79PubMedCrossRefGoogle Scholar
  16. Nissen S, Tuzcu E, Schoenhagen P, Brown BG, Ganz P, Vogel R et al (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 291:1071–1080PubMedCrossRefGoogle Scholar
  17. Nissen S, Tuzcu E, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J et al (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352:29–38PubMedCrossRefGoogle Scholar
  18. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA (2007) Genetic determinants of static intolerance. Lipids Health Dis 6:7–11PubMedCrossRefGoogle Scholar
  19. Omar MA, Wilson JP, Cox TS (2001) Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35:1096–1107PubMedCrossRefGoogle Scholar
  20. Paiva H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM et al (2005) High-dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial. Clin Pharmacol Ther 78:60–68PubMedCrossRefGoogle Scholar
  21. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C (2002) ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke 33:2337–2341PubMedCrossRefGoogle Scholar
  22. Pedersen TR (2001) Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management. Am J Cardiol 87:8–12CrossRefGoogle Scholar
  23. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL et al (2007) Mitochondrial dysfunction in the elderly: Possible role in insulin resistance. Science 300:1140–1142 doi:10.1126/science.1082889 CrossRefGoogle Scholar
  24. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ et al (2002a) Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581–585PubMedGoogle Scholar
  25. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ et al (2002b) Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581–585PubMedGoogle Scholar
  26. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ et al (2002c) Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581–585PubMedGoogle Scholar
  27. Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH (2004) Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis 177:183–188PubMedCrossRefGoogle Scholar
  28. Ploutz-Snyder LL, Giamis EL (2001) Orientation and familiarization to 1RM strength testing in old and young women. J Strength Cond Res 15:519–523PubMedCrossRefGoogle Scholar
  29. Schick BA, Laaksonen R, Frohlich JJ, Paiva H, Lehtimaki T, Humphries KH et al (2007) Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther 81:650–653PubMedCrossRefGoogle Scholar
  30. Sinzinger H, Schmid P, O’Grady J (1999) Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment. Atherosclerosis 143:459–460PubMedCrossRefGoogle Scholar
  31. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR (1997) Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 46:1206–1210PubMedCrossRefGoogle Scholar
  32. Turunen M, Olsson J, Dallner G (2004) Metabolism and function of coenzyme Q. Biochim Biophys Acta 1660:171–199PubMedCrossRefGoogle Scholar

Copyright information

© American Aging Association, Media, PA, USA 2008

Authors and Affiliations

  • Tinna Traustadóttir
    • 1
  • Anthoney A. Stock
    • 1
  • S. Mitchell Harman
    • 1
  1. 1.Kronos Longevity Research InstitutePhoenixUSA

Personalised recommendations